Conning Inc’s AstraZeneca AZN Stock Holding History

Conning Inc’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-6,530	Closed	-$416K	–	546
2015 Q2	$416K	Hold	6,530	–	–	0.02%	423
2015 Q1	$447K	Buy	+6,530	New	+$454K	0.02%	409

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Cambiar Investors Denver, Colorado $2.3B AUM 24.77% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Conning Inc's AZN Position: Q3 2015 in Review

Conning Inc sold out of AstraZeneca (AZN) in Q3 2015, closing a stake of 6,530 shares — an estimated $416K sold.

Conning Inc first reported a position in AZN in Q1 2015 and held it in 2 quarters. The position peaked at $447K in Q1 2015. 371 funds tracked by Wall St. Rank hold AZN as of Q3 2015.

Conning Inc reported no remaining AstraZeneca position as of Q3 2015 after selling out during the quarter.
Conning Inc sold 6,530 AstraZeneca shares in Q3 2015, an estimated $416K.
Conning Inc first reported a position in AstraZeneca in Q1 2015 and held it in 2 quarters.
Conning Inc's AstraZeneca position peaked at $447K in Q1 2015.
371 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2015.

Based on Conning Inc's 13F filing for Q3 2015, filed 23 Oct 2015.